# Vir Biotechnology Inc. (VIR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $11.38, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Vir Biotechnology Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 6.4×**. Each dollar of revenue is priced at 6.4×.
- **Price / book: 2.3×**. The shares trade at 2.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -10.6%** (5-yr avg -21.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -92.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -638.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -57.2%**. Return on equity is negative because earnings are negative.
- **Return on assets: -25.1%**. Each dollar of assets produces -25.1% of profit.

## Growth
- **Revenue growth (1 yr): -7.6%** (3-yr -65.1%/yr, 5-yr -2.1%/yr). Revenue fell 7.6% over the last year, against -2.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 17.5%**. Earnings per share rose 17.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 5.54** (quick 5.54). Current assets cover the next year's liabilities 5.54 times.
- **Altman Z-score: 4.93**. A Z-score of 4.93 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Vir Biotechnology Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Vir Biotechnology Inc.; the consensus is strong_buy, with an average price target of $20.78 (+83% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 121.5%** (YTD 88.8%, 3-mo 31.6%). The shares are up 121.5% over twelve months including dividends.
- **From 52-week high: -4.6%** (139.7% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 67**. An RSI of 67 is neutral.
- **Beta (1 yr): 1.75** (volatility 65%). Beta of 1.75 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VIR · Page: https://foliofundamentals.com/stocks/vir

Not investment advice.